Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
What Is The Predicted Market Size Of The Peptide And Anticoagulant Drugs Industry By 2029?
The market size of peptide and anticoagulant drugs has seen a significant expansion in the past few years. The market is projected to rise from $1.41 billion in 2024 to $1.54 billion in 2025, with a compound annual growth rate (CAGR) of 9.6%. The surge during the historical period can be traced back to factors such as enhanced expenditure in healthcare, amplified investments in healthcare, rising market liberalization, an increase in the global number of patients with infections, and a surge in the occurrence of genetic disorders.
The market for peptide and anticoagulant drugs is predicted to experience robust expansion in the upcoming years. It is projected to reach a value of “$2.25 billion in 2029” exhibiting a compound annual growth rate (CAGR) of 9.9%. Multiple factors such as the growing incidence of chronic health conditions, an aging demographic, the ever increasing diagnosis of cancer, the expansion of emerging markets and the escalating cases of cardiovascular ailments can explain the anticipated growth during the forecast period. The forecast period is also expected to see key trends including progressive biotechnological advancements, the evolution of drug delivery technology, enhancements in diagnostic methods, advancements in the field of pharmacology and the formulation of new anticoagulant products.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21252&type=smp
Which Key Factors Are Fueling Growth In The Peptide And Anticoagulant Drugs Market?
The projected growth of the peptide and anticoagulant drugs market is linked to the increasing prevalence of chronic diseases. These are health conditions that last a long time, often encompassing years or a person’s lifetime. Factors such as aging populations, unhealthy lifestyles, and a higher incidence of risks like obesity, hypertension, and diabetes are fueling the rise in chronic diseases. Peptide and anticoagulant drugs manage chronic conditions like thrombosis, cardiovascular diseases, and stroke by blocking blood clot formation and inducing specific disease pathways for enhanced patient results. Reports from the Centers for Disease Control and Prevention, in May 2023, documented that heart disease and cancer deaths in the US amounted to 695,547 in 2022, marking an increase from the preceding year’s count of 605,213 in 2021. As a result, the escalating prevalence of chronic diseases is propelling the peptide and anticoagulant drugs market’s expansion.
What Are The Main Segment Classifications In The Peptide And Anticoagulant Drugs Market?
The peptide and anticoagulant drugs market covered in this report is segmented –
1) By Type: Hormonal, Antibiotic, Ace Inhibitor, Antifungal, Other Types
2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
4) By Application: Infectious Diseases, Gynecology, Cancer, Diabetes, Cardiology, Osteoporosis, Other Applications
5) By End-users: Hospitals, Specialty Clinics, Homecare, Other End-users
Subsegments:
1) By Hormonal: Peptide Hormones, Steroid Hormones, Thyroid Hormones, Other Hormones
2) By Antibiotic: Beta-Lactams, Macrolides, Tetracyclines, Fluoroquinolones, Other Antibiotics
3) By ACE Inhibitor: Captopril, Enalapril, Lisinopril, Ramipril, Other ACE Inhibitors
4) By Antifungal: Azoles, Echinocandins, Polyenes, Allylamines, Other Antifungals
5) By Other Types: Immunosuppressants, Antineoplastic Agents, Cardiovascular Drugs, Other Peptide And Anticoagulant Drugs
How Are Industry Trends Steering The Expansion Of The Peptide And Anticoagulant Drugs Market?
Major players in the peptide and anticoagulant drugs industry are directing their focus towards developing advancements in anticoagulant therapies like oral anticoagulants, with the aim to increase effectiveness, foster patient compliance, and minimize the likelihood of hemorrhage complications. An oral anticoagulant is a medication consumed orally to hinder the formation of blood clots by impeding clotting agents in the blood. As an example, Cadrenal Therapeutics Inc., an American pharmaceutical company, was granted the Orphan Drug Designation (ODD) by the Food and Drug Administration of the U.S. in April 2024 for its late-stage oral anticoagulant, tecarfarin. Tecarfarin is created to be a novel and reversible blood-thinning drug targeting the reduction of heart attack, stroke, and mortality risks due to blood clots in patients with rare cardiovascular conditions. The ODD is specifically relevant to the prevention of thromboembolism and thrombosis in patients who have been fitted with mechanical circulatory support devices like left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), ventricular assist devices (VADs), biventricular assist devices, and total artificial hearts.
Which Companies Are Contributing Significantly To The Peptide And Anticoagulant Drugs Market Growth?
Major companies operating in the peptide and anticoagulant drugs market are Pfizer Inc., Merck & Co. Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Sanofi S.A., Abbott Laboratories, Novartis AG, Novo Nordisk A/S, Viatris Inc., Baxter International Inc., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Bachem Holding AG, Bharat Serums and Vaccines Limited, Wockhardt Limited, AmbioPharm Inc., MITS Healthcare Private Limited, Siddha Pharmacy, Circle Pharma Inc., Tenwel Pharmaceuticals Pvt. Ltd.
Access The Complete Report Here:
Which Region Holds The Greatest Opportunity For Peptide And Anticoagulant Drugs Market Expansion?
North America was the largest region in the peptide and anticoagulant drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and anticoagulant drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=21252&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
